Roche breakthrough in Avastin trial
In a clinical trial, the Swiss pharmaceutical giant Roche has successfully used a biological drug against an aggressive type of ovarian cancer.
af KRESTEN MORTEN MUNKSGAARD
Women with ovarian cancer, who experience relapses shortly after their chemotherapy treatments, could buy significant amounts of time until the next setback by being treated with the biological drug Avastin (bevacizumab).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
